Promising new combo aims to shrink Early-Stage lymphoma before radiation
NCT ID NCT07574528
First seen May 20, 2026 · Last updated Jun 14, 2026 · Updated 7 times
Summary
This study tests a new combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation as a first treatment for people newly diagnosed with stage I or II extranodal NK/T-cell lymphoma, a rare blood cancer. About 47 adults will receive the drug combo first, then radiation, to see if it leads to a complete disappearance of cancer. The goal is to improve outcomes compared to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NKTCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, 广东省 - Guangdong Sheng, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.